Role of FABP3 as Biomarker in Alzheimer's Disease and Synucleinopathies

References

• Jack CJ , BennettDA, BlennowKet al. 2018 NIA-AA research framework to investigate the Alzheimer's disease continuum. Alzheimers Dement.14(4), 535–562 (2018).
   PubMed Web of Science ®Google Scholar
• Johnson KA , FoxNC, SperlingRAet al. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. doi:10.1101/cshperspect.a006213 (2012) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Villemagne VL , DoréV, BurnhamSCet al. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nature reviews doi:10.1038/nrneurol.2018.9 (2018) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Rosén C , HanssonO, BlennowKet al. Fluid biomarkers in Alzheimer's disease – current concepts. Mol. Neurodegener.8, 20 (2013).
   PubMed Web of Science ®Google Scholar
• Mattson MP . Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. NPJ Aging Mech. Dis. doi:10.1038/npjamd.2015.3 (2015) ( Epub ahead of print).
   PubMedGoogle Scholar
• Jack CR Jr, Knopman DS , WeigandSDet al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurolo. doi:10.1002/ana.22628 (2012) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Jack CJ , WisteHJ, Vemuri KnopmanDet al. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology82, 1605–1612 (2014).
   PubMed Web of Science ®Google Scholar
• Okonkwo OC , AloscoML, GriffithHRet al. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch. Neurol.67, 688–696 (2010).
   PubMedGoogle Scholar
• Steinman L . Nuanced roles of cytokines in three major human brain disorders. J. Clin. Invest.118, 3557–3563 (2008).
   PubMed Web of Science ®Google Scholar
• Perry VH , CunninghamC, HolmesC. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol.7, 161–167 (2007).
   PubMed Web of Science ®Google Scholar
• Reitz C . Dyslipidemia and the risk of Alzheimer's disease. Curr. Atheroscler. Res.15, 307 (2013).
   PubMed Web of Science ®Google Scholar
• Walter J , van Echten-DeckertG. Cross-talk of membrane lipids and Alzheimer-related proteins. Mol. Neurodegener.8, 34 (2013).
   PubMed Web of Science ®Google Scholar
• Soderberg M , EdlundC, KristenssonKet al. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids.26 (6), 421–425 (1991).
   PubMed Web of Science ®Google Scholar
• Bjerke M , ZetterbergH, EdmanAet al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J. Alzheimers Dis.27, 665–676 (2011).
   PubMed Web of Science ®Google Scholar
• Tanaka T , IwawakiD, SakamotoMet al. Mechanisms of accumulation of arachidonate in phosphatidylinositol in yellowtail. A comparative study of acylation systems of phospholipids in rat and the fish species Seriola quinqueradiata. Eur. J. Biochem.270, 1466–1473 (2003).
   PubMedGoogle Scholar
• Moullé VSF , CansellC, LuquetandSet al. The multiple roles of fatty acid handling proteins in brain. Front. Physiol.3, 285 (2012).
   PubMed Web of Science ®Google Scholar
• Storch J , CorsicoB. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu. Rev. Nutr.28, 73–95 (2008).
   PubMed Web of Science ®Google Scholar
• Owada Y . Fatty acid binding protein: localization and functional significance in the brain. Tohoku J. Exp. Med.214, 213–220 (2008).
   PubMed Web of Science ®Google Scholar
• Storch J , ThumserAE. The fatty acid transport function of fatty acid-binding proteins. Biochim. Biochim. Biophys. Acta.1486, 28–44 (2000).
   PubMed Web of Science ®Google Scholar
• Zimmerman AW , VeerkampJH. New insights into the structure and function of fatty acid-binding proteins. Cell. Mol. Life Sci.59, 1096–1116 (2002).
   PubMed Web of Science ®Google Scholar
• Veerkamp JH , MaatmanRG. Cytoplasmic fatty acid-binding proteins: their structure and genes. Prog. Lipid Res.34, 17–52 (2001).
   Google Scholar
• Wassall SR , StillwellW. Polyunsaturated fatty acid cholesterol interactions: domain formation in membranes. Biochim. Biophys. Acta.1788 (1), 24–32 (2009).
   PubMed Web of Science ®Google Scholar
• Janssen CI , KiliaanAJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog. Lipid Res.53, 1–17 (2014).
   PubMed Web of Science ®Google Scholar
• Gamoh S , HashimotoM, SugiokaK. Chronic administration of docosahexaenoic acid improves reference memoryrelated learning ability in young rats. Neuroscience93(1), 237–241 (1999).
   PubMed Web of Science ®Google Scholar
• Oddo S , CaccamoA, ShepherdJD. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron39(3), 409–421 (2003).
   PubMed Web of Science ®Google Scholar
• Grimm MW , ZimmerVC, LehmannJet al. The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease. BioMed. Res. Int. doi:10.1155/2013/814390 (2013) ( Epub ahead of print).
   Google Scholar
• Lautner R , PalmqvistS, MattssonNet al. Alzheimer's disease neuroimaging I apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry71, 1183–1191 (2014).
   PubMed Web of Science ®Google Scholar
• Wood LP . Lipidomics of Alzheimer's disease: current status. Alzheimers Res. Ther.4, 5 (2012).
   PubMed Web of Science ®Google Scholar
• Bass NM , RaghuphatyE, RhoadsDEet al. Partial purification of molecular weight 12000 fatty acid binding protein from rat brain and their effect on synaptosomal Na+-dependent amino acid uptake. Biochemistry23, 6539–6544 (1984).
   PubMed Web of Science ®Google Scholar
• Murphy EJ , OwadaY, KitanakaNet al. Brain arachidonic acid incorporation is decreased in heart fatty acid-binding protein gene-ablated mice. Biochemistry44, 6350–6360 (2005).
   PubMed Web of Science ®Google Scholar
• Liu RZ , MitaR, BeaulieuMet al. Fatty acid binding proteins in brain development and disease. Int. J. Dev. Biol.54, 1229–1239 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas M , PelleieuxS, VitaleNet al. Dietary arachidonic acid as a risk factor for age-associated neurodegenerative diseases: potential mechanisms. Biochimie1, 10 (2016).
   Google Scholar
• Takeuki Y , FukunagaK. Differential subcellular localization of two dopamine D2 receptor isoformos in tranfected NG108-15 cells. J. Neurochem.85, 1064–1074 (2003).
   PubMed Web of Science ®Google Scholar
• Seeman P . Are dopamine D2 receptors out of control in psychosis?Prog. Neuropsychopharmacol. Biol. Psychiatry46, 146–152 (2013).
   PubMed Web of Science ®Google Scholar
• Sharon R , GoldbergMS, Bar-JosefIet al. α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA98, 9110–9115 (2001).
   PubMed Web of Science ®Google Scholar
• Maroteaux L , CampanelliJT, SchellerRH. Synuclein: a neuron-specific protein localized in the nucleus and presynaptic nerve terminal, J. Neurosci.8, 2804–2815 (1988).
   PubMed Web of Science ®Google Scholar
• Castagnet PI , GolovkoMY, Barcelo'-CoblijnGCet al. Fatty acid incorporation is decreased in atrocities cultured from α-synuclein gene-ablated mice. J. Neurochem.94(3), 839–849 (2005).
   PubMed Web of Science ®Google Scholar
• Sharon R , Bar-JosephI, FroschMPet al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron37, 583–595 (2003).
   PubMed Web of Science ®Google Scholar
• Dubois B , FeldmanHH, JacovaCet al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol.9, 1118–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Dubois B , FeldmanHH, JacovaCet al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6, 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Li G , SokalI, QuinnJF, LeverenzJBet al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology.69, 631–639 (2007).
   PubMed Web of Science ®Google Scholar
• De Meyer G , ShapiroF, VandersticheleHet al. Diagnosis independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol.67, 949–956 (2010).
   PubMed Web of Science ®Google Scholar
• Visser PJ , VerheyF, KnolDLet al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol.8, 619–627 (2009).
   PubMed Web of Science ®Google Scholar
• Fagan AM , RoeCM, XiongCet al. Cerebrospinal fluid tau/β-amyloid (42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol.64, 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Lewczuk P , RiedererP, O'BryantSEet al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J. Biol. Psychiatry doi:10.1080/15622975.2017.1375556 (2018) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Britschgi M , RufibachK, Bauer HuangSLet al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signalling proteome. Mol. Cell. Proteomics10, 1–11 (2011).
   Web of Science ®Google Scholar
• Rosén C , MattssonN, JohanssonPMet al. Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases. Front. Aging Neurosci.3–1 (2011).
   PubMed Web of Science ®Google Scholar
• Hu WT , Chen-PlotkinA, ArnoldSEet al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol.119, 669–678 (2010).
   PubMed Web of Science ®Google Scholar
• Shaw LM , VandersticheleH, Knapik-CzajkaMet al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol.121(5), 597–609 (2011).
   PubMed Web of Science ®Google Scholar
• Chiasserini D , ParnettiL, AndreassonUet al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J. Alzheimers Dis.22, 1281–1288 (2010).
   PubMed Web of Science ®Google Scholar
• Harari O , CruchagaC, Kauwe JSKAet al. Ptau-Aβ42 ratio as a continuous trait for biomarker discovery for early stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol. Psychiatry75(9), 723–731 (2014).
   PubMed Web of Science ®Google Scholar
• Bjerkeb M , KernaS, BlennowKet al. Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8 years. J. Alzheimers Dis.49, 733–741 (2016).
   PubMed Web of Science ®Google Scholar
• Desikan R , ThompsonWK, HollandDet al. Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration. Mol. Neurodegen.8, 39 (2013).
   PubMed Web of Science ®Google Scholar
• Maroteaux L , CampanelliJT, SchellerRH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci.8, 2804–2815 (1988).
   PubMed Web of Science ®Google Scholar
• Spillantini MG , CrowtherRA, JakesRet al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA95, 6469–6473 (1998).
   PubMed Web of Science ®Google Scholar
• Conway KA , HarperJD, LansburyPT. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early onset Parkinson disease. Nat. Med.4, 1318–1320 (1998).
   PubMed Web of Science ®Google Scholar
• Winner B , JappelliR, MajiSKet al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA108, 4194–4199 (2011).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B , El-AgnafOM, MarcusKet al. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med.4, 683–699 (2010).
   PubMed Web of Science ®Google Scholar
• Suzuki M , SangoK, WadaK, NagaiY. Pathological role of lipid interaction with α-synuclein in Parkinson's disease. Neurochem. Int. doi:10.1016/j.neuint.2017.12.014 (2018) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Sharon R , Bar-JosephI, MirickGEet al. Altered fatty acid composition of dopaminergic neurons expressing α-synuclein and human brains with α-synucleinopathies. J. Biol. Chem.278, 49874–49881 (2003).
   PubMed Web of Science ®Google Scholar
• Shioda N , YabukiY, KobayashiYet al. FABP3 protein promotes α-Synuclein oligomerization associated with 1 methyl-1,2,3,6-tetrahydropiridine induced neurotoxicity. J. Biol. Chem.289(27), 18957–18965 (2014).
   PubMed Web of Science ®Google Scholar
• Zimmer L , Delion-VancasselS, DurandGet al. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n- 3 polyunsatured fatty acid. J. Lipid Res.41, 32–40 (2000).
   PubMed Web of Science ®Google Scholar
• Eusebi P , GiannandreaD, BiscettiLet al. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: a systematic review and meta-analysis. Mov. Disord.32, 1389–1400 (2017).
   PubMed Web of Science ®Google Scholar
• Parnetti L , CastriotoA, ChiasseriniDet al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol.9, 131–140 (2013).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B , SteinackerP, BahnEet al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodeg. Dis.4, 366–375 (2007).
   PubMed Web of Science ®Google Scholar
• Wada-Isoe K , ImamuraK, KitamayaMet al. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J. Neurol. Sci.266, 20–24 (2008).
   PubMed Web of Science ®Google Scholar
• Teunissen CE , VeerhuisaR, De VenteJet al. Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur. J. Neurol.18, 865–871 (2011).
   PubMed Web of Science ®Google Scholar
• Backstrom DC , Eriksson DomellofM, LinderJet al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. doi:10.1001/jamaneurol.2015.1449 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Chiasserini D , BiscettiL, EusebiPet al. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Alzheimers Res. Ther.9, 52 (2017).
   PubMed Web of Science ®Google Scholar